Reply to COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors
- PMID: 33721356
- PMCID: PMC8251462
- DOI: 10.1002/cncr.33431
Reply to COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors
Conflict of interest statement
The authors made no disclosures.
Comment on
-
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.Cancer. 2020 Dec 1;126(23):5069-5076. doi: 10.1002/cncr.33160. Epub 2020 Sep 10. Cancer. 2020. PMID: 32910456
-
COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.Cancer. 2021 Jun 1;127(11):1937-1938. doi: 10.1002/cncr.33432. Epub 2021 Mar 15. Cancer. 2021. PMID: 33721325 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
